FINNENCE ▪ THE WIRE FILE
THE WIRE · № 68910
News▲ Bullish
Emerging Biotechs Standardize on Veeva Basics to Accelerate Drug Development

KINDNews
DIRECTION▲ Bullish
SOURCES2
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-10-07 11:03 UTC
LAST UPDATE2026-10-07 11:03 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Veeva expanding its customer base among emerging biotechs supports recurring software revenue.
Veeva deepens biotech software footprint
CATALYST TO WATCH
Customer count growth in future quarters
MAIN RISK
Small biotechs may cut software spend
FULL DISPATCH
More than 175 biotechs use pre-configured applications to streamline operations PLEASANTON, Calif., Oct. 7, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that more than 175 emerging biotechs are establishing a technology foundation with Veeva Basics. Biotechs are...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
2 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Mediar Therapeutics Completes Enrollment in Phase 2 WISPer Trial of MTX-463 in Idiopathic Pulmonary Fibrosis (IPF)2026-10-07 11:08 UTC
Mediar Therapeutics Completes Enrollment in Phase 2 WISPer Trial of MTX-463 in Idiopathic Pulmonary Fibrosis (IPF)2026-10-07 11:08 UTC
→CORRELATIONshares Healthcare
Health Transformation Alliance and State Financial Officers Foundation Announce Corporate Health Plan Fiduciary Scorecard2026-10-07 11:17 UTC
Health Transformation Alliance and State Financial Officers Foundation Announce Corporate Health Plan Fiduciary Scorecard2026-10-07 11:17 UTC
→CORRELATIONshares Healthcare
Infinitus Launches FieldForce to Extend the Reach of Pharmaceutical Sales and Reimbursement Teams2026-10-07 11:30 UTC
Infinitus Launches FieldForce to Extend the Reach of Pharmaceutical Sales and Reimbursement Teams2026-10-07 11:30 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.